Table 1

Demographics and clinical characteristics of patients used for the serum and urine biomarker validation studies

Serum1

Urine1


No.

28

27

Female, no. (%)

25 (89.3)

21 (77.8)

Age, mean +/- SE, years

37.3 ± 1.8

34.6 ± 2.3

Race, African American/Hispanic/Caucasian, no.

17/8/2

13/12/1

SLEDAI, median (interquartile)

10 (3 to 16)

10 (2 to 16)

Renal SLEDAI, median (interquartile)

5 (0 to 8)

5 (0 to 8)

No. of patients with renal SLEDAI = 0 (%)

10 (35.7)

9 (33.3)

Protein:creatinine ratio, mg/mg, mean +/- SE

2.0 ± 0.5

2.3 ± 0.5

Serum Cr, mg/dl, mean +/- SE

1.3 ± 0.2

1.4 ± 0.2

Comorbidities, no. (%)

Diabetes Melitus

3 (10.7)

4 (14.8)

Hypertension

20 (71.4)

20 (74.1)

Dyslipidemia

12 (42.8)

15 (55.6)

Cardiovascular disease

4 (14.3)

3 (11.1)

Anemia

16 (57.1)

18 (66.7)

Antiphospholipid syndrome

3 (10.7)

3 (11.1)

Venous thromboembolism

3 (10.7)

3 (11.1)

Others

14 (50%)

11 (40.7)

Current medications, no. (%)

Prednisone

17 (60.7)

20 (74)

Mycophenolic acid

7 (25)

7 (25.9)

Cyclophosphamide

1 (3.6)

2 (7.4)

Azathioprine/MTX

6 (21.4)

3 (11.1)

Cyclosporine/Tacrolimus

2 (7.1)

1 (3.7)

Hydrochloroquine

12 (42.9)

11 (40.7)

Angiotensin blocking agents

14 (50)

16 (59.3)


1Note that 16 SLE patients had provided both serum and urine samples.

Vanarsa et al. Arthritis Research & Therapy 2012 14:R182   doi:10.1186/ar4012

Open Data